Literature DB >> 34373564

Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis.

Diana Prieto-Peña1, Sara Remuzgo-Martínez1, Fernanda Genre1, Verónica Pulito-Cueto1, Belén Atienza-Mateo1,2, Javier Llorca3, Belén Sevilla-Pérez4, Norberto Ortego-Centeno5, Ana Marquez6,7, Leticia Lera-Gómez1, María Teresa Leonardo8, Ana Peñalba8, Javier Narváez9, Luis Martín-Penagos10, Emilio Rodrigo10, José A Miranda-Filloy11, Luis Caminal-Montero12, Paz Collado13, Javier Sánchez Pérez14, Diego de Argila14, Esteban Rubio15, Manuel León Luque15, Juan María Blanco-Madrigal16, Eva Galíndez-Agirregoikoa16, Oreste Gualillo17, Javier Martín6, Santos Castañeda18, Ricardo Blanco1, Miguel A González-Gay1,19,20, Raquel López-Mejías21.   

Abstract

Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34373564     DOI: 10.1038/s41598-021-95762-5

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  6 in total

1.  Henoch-Schönlein purpura (IgA vasculitis): the paradox of the different incidence and clinical spectrum in children and adults.

Authors:  Miguel A González-Gay; Ricardo Blanco; Santos Castañeda
Journal:  Clin Exp Rheumatol       Date:  2017-01-27       Impact factor: 4.473

2.  Interleukin 8 gene polymorphism is associated with increased risk of nephritis in cutaneous vasculitis.

Authors:  Mahsa M Amoli; Wendy Thomson; Ali H Hajeer; Maria C Calviño; Carlos Garcia-Porrua; William E R Ollier; Miguel A Gonzalez-Gay
Journal:  J Rheumatol       Date:  2002-11       Impact factor: 4.666

3.  Hypersensitivity vasculitis and Henoch-Schönlein purpura: a comparison between the 2 disorders.

Authors:  B A Michel; G G Hunder; D A Bloch; L H Calabrese
Journal:  J Rheumatol       Date:  1992-05       Impact factor: 4.666

4.  Interleukin 1 receptor antagonist gene polymorphism is associated with severe renal involvement and renal sequelae in Henoch-Schönlein purpura.

Authors:  Mahsa M Amoli; Wendy Thomson; Ali H Hajeer; Maria C Calviño; Carlos Garcia-Porrua; William E R Ollier; Miguel A Gonzalez-Gay
Journal:  J Rheumatol       Date:  2002-07       Impact factor: 4.666

5.  Interleukin 1beta gene polymorphism association with severe renal manifestations and renal sequelae in Henoch-Schönlein purpura.

Authors:  Mahsa M Amoli; Maria C Calviño; Carlos Garcia-Porrua; Javier Llorca; William E R Ollier; Miguel A Gonzalez-Gay
Journal:  J Rheumatol       Date:  2004-02       Impact factor: 4.666

6.  Interleukin 1 beta (IL1ß) rs16944 genetic variant as a genetic marker of severe renal manifestations and renal sequelae in Henoch-Schönlein purpura.

Authors:  Raquel López-Mejías; Fernanda Genre; Sara Remuzgo-Martínez; Belen Sevilla Pérez; Santos Castañeda; Javier Llorca; Norberto Ortego-Centeno; Begoña Ubilla; Verónica Mijares; Trinitario Pina; Vanesa Calvo-Río; Jose A Miranda-Filloy; Antonio Navas Parejo; Diego Argila; Javier Sánchez-Pérez; Esteban Rubio; Manuel León Luque; Juan María Blanco-Madrigal; Eva Galíndez-Aguirregoikoa; Javier Martín; Ricardo Blanco; Miguel A González-Gay
Journal:  Clin Exp Rheumatol       Date:  2016-02-01       Impact factor: 4.473

  6 in total
  1 in total

Review 1.  Consensus evidence-based recommendations for treat-to-target management of immunoglobulin A vasculitis.

Authors:  Mohammed Hassan Abu-Zaid; Samia Salah; Hala M Lotfy; Maha El Gaafary; Hala Abdulhady; Samar Abd Alhamed Tabra; Hala Salah; Yomna Farag; Mervat Eissa; Sheren Esam Maher; Ahmed Radwan; Amira Tarek El-Shanawany; Basma M Medhat; Dalia El Mikkawy; Doaa Mosad Mosa; Ghada El Deriny; Mohamed Mortada; Naglaa S Osman; Nermeen Ahmed Fouad; Nourhan Elameen Elkaraly; Sally S Mohamed; Waleed A Hassan; Youmna A Amer; Samah Ismail Nasef; Yasser El Miedany
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-12-09       Impact factor: 5.346

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.